Menu
Recruiting NCT06438627

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

Phase III Interventional Nasopharyngeal Carcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: TPC combined with Apatinib and Camrelizumab, GP Combined With Camrelizumab.
Who it may be relevant to
Registry conditions: Nasopharyngeal Carcinoma. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Efficacy and Safety of Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab vs Gemcitabine, Cisplatin Combined With Camrelizumab for Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Nasopharyngeal Carcinoma: A Prospective, Controlled, Open-Label, Multicenter Phase 3 Clinical Trial

Overview

This study aims to evaluate the efficacy and safety of the TPC regimen (nab-paclitaxel, cisplatin, and capecitabine) combined with apatinib and camrelizumab versus the GP regimen (gemcitabine and cisplatin) combined with camrelizumab for the treatment of high-risk regionally advanced nasopharyngeal carcinoma with a high risk of distant metastasis. The evaluation will be conducted through a prospective, controlled, open-label, multicenter phase 3 clinical trial in areas with high incidence of nasopharyngeal carcinoma.

Detailed description

IMPORTANCE: Safe and effective therapies for untreated, advanced locally advanced nasopharyngeal carcinoma remain an unmet need.

OBJECTIVE:This study aims to evaluate the efficacy and safety of the TPC regimen (nab-paclitaxel, cisplatin, and capecitabine) combined with apatinib and camrelizumab versus the GP regimen (gemcitabine and cisplatin) combined with camrelizumab for the treatment of high-risk regionally advanced nasopharyngeal carcinoma with a high risk of distant metastasis. The evaluation will be conducted through a prospective, controlled, open-label, multicenter phase 3 clinical trial in areas with high incidence of nasopharyngeal carcinoma.

Interventions

  • Drug TPC combined with Apatinib and Camrelizumab
    Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab
  • Drug GP Combined With Camrelizumab
    Gemcitabine, Cisplatin regimen Combined With Camrelizumab

Primary outcome measures

  • 3-years FFS [Time frame: up to 3 years]
Secondary outcome measures (4)
  • DMFS [Time frame: up to 3 years]
  • OS [Time frame: up to 3 years]
  • LRFS [Time frame: up to 3 years]
  • ORR [Time frame: up to 3 years]

Eligibility criteria

Inclusion criteria

  • Pathologically confirmed WHO type II or III;
  • Staging TanyN3M0 (UICC/AJCC 8th edition);
  • Treatment-naive patients with no history of other malignancies;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
  • Age 18-65 years;
  • Neutrophils ≥1.5×10\^9/L, platelets ≥100×10\^9/L, hemoglobin ≥90 g/L, transaminases <2.5 times the upper limit of normal, total bilirubin <1.5 times the upper limit of normal, creatinine <1.5 times the upper limit of normal; activated partial thromboplastin time and international normalized ratio <1.5 times the upper limit of normal;
  • Signed informed consent form.

Exclusion criteria

  • Known or suspected allergy to the study drugs, or pregnant/perinatal women;
  • Inability to comply with regular follow-up due to psychological, social, familial, or geographical reasons;
  • Severe dysfunction of critical organs such as the heart, lungs, liver, or kidneys (e.g., decompensated heart, lung, renal, or liver failure) that precludes tolerance to chemoradiotherapy;
  • Severe uncontrolled infection or internal medical disease;
  • Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); untreated active hepatitis (hepatitis B defined as HBV-DNA ≥500 IU/ml, exclusion if normal liver function and on antiviral medication for more than one week; hepatitis C defined as HCV-RNA above the lower limit of detection) or coinfection with hepatitis B and C;
  • Factors affecting drug administration, distribution, metabolism, or excretion such as psychiatric disorders, central nervous system abnormalities, chronic diarrhea, ascites, or pleural effusion;
  • Poorly controlled hypertension despite antihypertensive treatment (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg);
  • Long-term use of immunosuppressants post-organ transplantation;
  • Known history of substance abuse or drug addiction;
  • History of other malignancies prior to enrollment;
  • Presence of other severe physical or mental illnesses or abnormal laboratory findings that may increase the risk of study participation, interfere with study results, or deemed unsuitable for participation by the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 2 centers
  • SunYat-senU — Guangzhou
  • Sun Yat sen Memorial Hospital — Guangzhou

Identifiers

NCT: NCT06438627 · SYSKY-2024-267-02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗